Rodent Idiopathic Pulmonary Fibrosis (IPF) Models

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease characterized by excessive extracellular matrix deposition, alveolar destruction, and loss of lung function. HKeyBio offers three well-validated rodent IPF models: (1) BLM induced SD rat model, the most widely used model for IPF research, induced by intratracheal bleomycin instillation; (2) SiO2 induced C57BL/6 mouse model, representing occupational silica-induced lung fibrosis; and (3) SiOx induced SD rat model, a chronic fibrotic lung disease model caused by crystalline silica exposure. These models recapitulate key human IPF features including body weight loss, inflammatory cell infiltration in BALF, lung function decline, and progressive fibrotic pathology (Masson trichrome, HE, PSR staining). They provide robust platforms for preclinical efficacy testing of novel anti-fibrotic therapeutics.

Quantity:
Availability:





Inquire Add to Basket

Product Description

Key Features & Benefits

Multiple etiologies – Chemical (BLM) and occupational (silica) induced models covering different IPF pathogenic mechanisms.

Comprehensive endpoints – Body weight, BALF cytology (inflammatory cells), lung function, histopathology (HE, Masson, PSR), pathology scoring.

Translational value – Ideal for testing anti-fibrotic drugs (nintedanib, pirfenidone), TGF-β inhibitors, and novel therapeutic candidates.

Species options – Rat and mouse models available to suit different experimental requirements.

IND-ready data packages – Studies can be conducted in accordance with GLP principles.

Technical Data & Validation

Representative data from our NHP Atopic Dermatitis (AD) Model：

BLM Induced C57BL/6 IPF Model

SiO₂ Induced C57BL/6 IPF Model

SiO₂ Induced Rat IPF Model

Applications

• Efficacy testing of anti-fibrotic drugs (nintedanib, pirfenidone, TGF-β inhibitors, lysyl oxidase inhibitors)

• Target validation for fibrotic pathways (TGF-β, CTGF, PDGF)

• Biomarker discovery (collagen deposition markers, inflammatory mediators)

• Mechanism of action (MOA) studies

• IND-enabling pharmacology and toxicology studies

Model Specifications

Parameter	BLM Induced Rat IPF	SiO2 Induced Mouse IPF	SiOx Induced Rat IPF
Species/Strain	Sprague-Dawley rat	C57BL/6 mouse	Sprague-Dawley rat
Induction method	Intratracheal bleomycin (single dose)	Intratracheal SiO2 (single dose)	Intratracheal crystalline silica (SiOx)
Study duration	14–28 days	45 days	28–56 days
Key endpoints	Body weight, BALF cytology (total cells, differential), lung function, histopathology (HE, Masson), pathology scoring	Body weight, lung function, pathology score, histopathology (HE, Masson, PSR)	Body weight, BALF neutrophils, histopathology (HE, Masson, PSR)
Data package	Raw data, analysis reports, BALF cytology, histology slides (HE, Masson, PSR), lung function data, bioinformatics (optional)

❓ Frequently Asked Questions

Q: What are the differences between BLM and silica induced IPF models?

A: BLM induces acute lung injury followed by fibrosis, mimicking drug-induced IPF. Silica models (SiO2, SiOx) represent occupational/environmental exposure, with slower progression and chronic inflammation, better reflecting human silicosis and some forms of IPF.

Q: Which model is best for testing anti-fibrotic drugs?

A: The BLM rat model is most widely accepted for anti-fibrotic drug screening due to its rapid onset and reproducibility. Silica models are preferred for studying chronic fibrosis and occupational lung disease interventions.

Q: Can these models be used for IND-enabling studies?

A: Yes. Studies can be conducted in accordance with GLP principles for regulatory submissions (FDA, EMA).

Q: Do you offer customized study protocols (e.g., different doses, time points, combination therapies)?

A: Absolutely. Our scientific team tailors induction protocols, treatment schedules, and endpoint analyses to your specific drug candidate.